Objectives: The study measures trends in the profile of patients with chronic hepatitis B virus linked to care in Italy. Methods: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used. Results: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time. Conclusion: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination / Brancaccio G.; Coco B.; Nardi A.; Quaranta M.G.; Tosti M.E.; Ferrigno L.; Cacciola I.; Messina V.; Chessa L.; Morisco F.; Milella M.; Barbaro F.; Ciancio A.; Russo F.P.; Coppola N.; Blanc P.; Claar E.; Verucchi G.; Puoti M.; Zignego A.L.; Chemello L.; Madonia S.; Fagiuoli S.; Marzano A.; Ferrari C.; Lampertico P.; Di Marco V.; Craxi A.; Santantonio T.A.; Raimondo G.; Brunetto M.R.; Gaeta G.B.; Kondili L.A.; Pasulo L.; Coppola C.; Pisano F.; Romano M.; Porcu C.; Bottalico I.F.; Cossiga V.; Tata X.; Sagnelli C.; Pierotti P.; Degasperi E.; Rosato V.; Badia L.; Ieluzzi D.; Monti M.; Bavetta M.G.; Cavalletto L.; Toniutto P.; Fornasiere E.; Colecchia A.; Ferrarese A.; Nardone G.; Rocco A.; Vigano M.; Foschi F.G.; Conti F.; Morsica G.; Salpietro S.; Torti C.; Costa C.; Federico A.; Dallio M.; Giorgini A.; Anselmo M.; De Leo P.; Zaltron S.; Cambianica A.; Piscaglia F.; Serio I.; Schivazappa S.; Mastroianni A.; Chidichimo L.; Massari M.; Mazzaro C.; Marrone A.; D'Amore F.M.; D'Offizi G.; Licata A.; Niro G.A.; Pollicino T.; Aghemo A.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - ELETTRONICO. - 129:(2023), pp. 266-273. [10.1016/j.ijid.2023.02.006]

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Ferrigno L.;Chessa L.;Milella M.;Blanc P.;Verucchi G.;Raimondo G.;Pisano F.;Badia L.;Torti C.;Federico A.;Anselmo M.;Zaltron S.;Piscaglia F.;Serio I.;
2023

Abstract

Objectives: The study measures trends in the profile of patients with chronic hepatitis B virus linked to care in Italy. Methods: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used. Results: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time. Conclusion: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.
2023
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination / Brancaccio G.; Coco B.; Nardi A.; Quaranta M.G.; Tosti M.E.; Ferrigno L.; Cacciola I.; Messina V.; Chessa L.; Morisco F.; Milella M.; Barbaro F.; Ciancio A.; Russo F.P.; Coppola N.; Blanc P.; Claar E.; Verucchi G.; Puoti M.; Zignego A.L.; Chemello L.; Madonia S.; Fagiuoli S.; Marzano A.; Ferrari C.; Lampertico P.; Di Marco V.; Craxi A.; Santantonio T.A.; Raimondo G.; Brunetto M.R.; Gaeta G.B.; Kondili L.A.; Pasulo L.; Coppola C.; Pisano F.; Romano M.; Porcu C.; Bottalico I.F.; Cossiga V.; Tata X.; Sagnelli C.; Pierotti P.; Degasperi E.; Rosato V.; Badia L.; Ieluzzi D.; Monti M.; Bavetta M.G.; Cavalletto L.; Toniutto P.; Fornasiere E.; Colecchia A.; Ferrarese A.; Nardone G.; Rocco A.; Vigano M.; Foschi F.G.; Conti F.; Morsica G.; Salpietro S.; Torti C.; Costa C.; Federico A.; Dallio M.; Giorgini A.; Anselmo M.; De Leo P.; Zaltron S.; Cambianica A.; Piscaglia F.; Serio I.; Schivazappa S.; Mastroianni A.; Chidichimo L.; Massari M.; Mazzaro C.; Marrone A.; D'Amore F.M.; D'Offizi G.; Licata A.; Niro G.A.; Pollicino T.; Aghemo A.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - ELETTRONICO. - 129:(2023), pp. 266-273. [10.1016/j.ijid.2023.02.006]
Brancaccio G.; Coco B.; Nardi A.; Quaranta M.G.; Tosti M.E.; Ferrigno L.; Cacciola I.; Messina V.; Chessa L.; Morisco F.; Milella M.; Barbaro F.; Ciancio A.; Russo F.P.; Coppola N.; Blanc P.; Claar E.; Verucchi G.; Puoti M.; Zignego A.L.; Chemello L.; Madonia S.; Fagiuoli S.; Marzano A.; Ferrari C.; Lampertico P.; Di Marco V.; Craxi A.; Santantonio T.A.; Raimondo G.; Brunetto M.R.; Gaeta G.B.; Kondili L.A.; Pasulo L.; Coppola C.; Pisano F.; Romano M.; Porcu C.; Bottalico I.F.; Cossiga V.; Tata X.; Sagnelli C.; Pierotti P.; Degasperi E.; Rosato V.; Badia L.; Ieluzzi D.; Monti M.; Bavetta M.G.; Cavalletto L.; Toniutto P.; Fornasiere E.; Colecchia A.; Ferrarese A.; Nardone G.; Rocco A.; Vigano M.; Foschi F.G.; Conti F.; Morsica G.; Salpietro S.; Torti C.; Costa C.; Federico A.; Dallio M.; Giorgini A.; Anselmo M.; De Leo P.; Zaltron S.; Cambianica A.; Piscaglia F.; Serio I.; Schivazappa S.; Mastroianni A.; Chidichimo L.; Massari M.; Mazzaro C.; Marrone A.; D'Amore F.M.; D'Offizi G.; Licata A.; Niro G.A.; Pollicino T.; Aghemo A.
File in questo prodotto:
File Dimensione Formato  
PIIS120197122300053X.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 564.38 kB
Formato Adobe PDF
564.38 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/957171
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact